Key Highlights
- WHO’s new designation labels Hepatitis D as a carcinogen.
- Risk of liver cancer rises 2‑6 fold in co‑infected individuals.
- Vaccination against Hepatitis B protects against HDV as well.
- Coverage remains below 60 % in many high‑risk regions.
Detailed Insights
Why HDV Matters: HDV is a dependent virus; it can only replicate in the presence of HBV, making co‑infection a deadly combination.
- Transmission mirrors HBV: blood contact, unprotected sex, and perinatal routes.
- In India, high‑risk groups—IV drug users, chronic HBV carriers—show higher prevalence than presumed.
- Diagnostic challenge: Detecting HDV‑RNA confirms active disease; antibody screening alone is insufficient.
Implications of the WHO Classification: The re‑labeling is expected to drive global funding, policy tightening, and accelerate drug approvals.
Current Treatment Landscape: Emerging antivirals (e.g., bulevirtide) hold promise, yet accessibility gaps persist in low‑income settings.
Key Concepts
- Carcinogen: A substance or pathogen that can initiate cancer.
- Co‑infection vs. Superinfection: Co‑infection occurs when two viruses infect simultaneously; superinfection refers to a second virus entering a host already infected with the first.
- HDV‑RNA: The viral genome segment whose presence in blood demonstrates ongoing replication.